Background: Thyroid Eye Disease (TED) is known to alter tissues of the orbital cavity, including the optic nerve. However, its effect on measured global Retinal Nerve Fiber Layer (gRNFL) is not well elucidated. This c...Background: Thyroid Eye Disease (TED) is known to alter tissues of the orbital cavity, including the optic nerve. However, its effect on measured global Retinal Nerve Fiber Layer (gRNFL) is not well elucidated. This case evaluates the effect of teprotumumab on gRNFL in a patient with moderate TED. Observations: A 60-year-old female with controlled ocular hypertension and moderate TED received 8 standard IV teprotumumab infusions. Comprehensive ocular evaluations were performed pre-, during-, and post-treatment. Bilateral gRNFL thickness decreased (10 m OD;12 m OS) at 4 months post-treatment start, persisting at 8 months, but recovered at 20 months. Conclusions and Importance: Teprotumumab treatment in patients with TED led to a transient bilateral decrease in gRNFL thickness, which was restored to baseline levels with no adverse events reported. Monitoring gRNFL changes in teprotumumab-treated patients is crucial as gRNFL thinning indicates retinal ganglion cell damage. Teprotumumabs ability to dampen the IGF-IR inflammatory cascade may have reduced retinal inflammation, leading to recovery.展开更多
目的:分析甲状腺相关眼病(Graves Ophthalmopathy,GO)患者的全自动非接触眼压计(NCT)与Goldman压平式眼压计(GAT)的测量结果,为临床上甲状腺相关眼病患者的眼压测量方法应用提供理论依据。方法:选择2011年2月-2020年3月期间,就诊于中山...目的:分析甲状腺相关眼病(Graves Ophthalmopathy,GO)患者的全自动非接触眼压计(NCT)与Goldman压平式眼压计(GAT)的测量结果,为临床上甲状腺相关眼病患者的眼压测量方法应用提供理论依据。方法:选择2011年2月-2020年3月期间,就诊于中山大学孙逸仙纪念医院眼科与内分泌科106例(106眼)诊断为甲状腺相关眼病(GO)患者。予以同时应用全自动非接触眼压计(NCT)与Goldman压平式眼压计(GAT)测量双眼眼压,依据GAT结果进行分组,对患者的临床资料进行统计学分析。结果:GO患者的GAT结果较NCT结果偏低(P<0.05)。眼压异常组的GO患者的眼球突出度、临床活动性评分(clinical activity score,CAS)及欧洲Graves眼病专家组(European Group on Graves' Obitopathy,EUGOGO)分级更严重(P均<0.05)。当GO患者的CAS≥3分时,NCT眼压值与GAT眼压值的结果不一致(P<0.05)。结论:当GO患者的CAS≥3分时,应用GAT评估GO患者的眼压。展开更多
目的:通过文献荟萃分析评价利妥昔单抗治疗中重度甲状腺相关眼病的疗效。方法:检索中国知网(CNKI)、万方、维普、中国生物医学、PubMed、Web of Science、OVID、Corhone Library、ClinicalTrial.gov等数据库从建库至2019-12-31发表的关...目的:通过文献荟萃分析评价利妥昔单抗治疗中重度甲状腺相关眼病的疗效。方法:检索中国知网(CNKI)、万方、维普、中国生物医学、PubMed、Web of Science、OVID、Corhone Library、ClinicalTrial.gov等数据库从建库至2019-12-31发表的关于利妥昔单抗治疗中重度甲状腺相关眼病的临床研究。以治疗前后甲状腺相关眼病的临床活动评分为疗效的主要判定指标。将检索到的文献应用RevMan 5.3统计学软件进行分析。结果:纳入了6项研究61例患者,其中2项为随机对照试验,4项为队列研究。Meta分析显示,应用利妥昔单抗治疗中重度甲状腺相关眼病,可使患者的临床活动评分显著降低[SMD=-5.04,95%CI(-7.08^-3.01),P<0.00001]。结论:利妥昔单抗可使中重度甲状腺相关眼病患者的临床活动评分显著下降,对疾病的控制有良好效果。展开更多
文摘Background: Thyroid Eye Disease (TED) is known to alter tissues of the orbital cavity, including the optic nerve. However, its effect on measured global Retinal Nerve Fiber Layer (gRNFL) is not well elucidated. This case evaluates the effect of teprotumumab on gRNFL in a patient with moderate TED. Observations: A 60-year-old female with controlled ocular hypertension and moderate TED received 8 standard IV teprotumumab infusions. Comprehensive ocular evaluations were performed pre-, during-, and post-treatment. Bilateral gRNFL thickness decreased (10 m OD;12 m OS) at 4 months post-treatment start, persisting at 8 months, but recovered at 20 months. Conclusions and Importance: Teprotumumab treatment in patients with TED led to a transient bilateral decrease in gRNFL thickness, which was restored to baseline levels with no adverse events reported. Monitoring gRNFL changes in teprotumumab-treated patients is crucial as gRNFL thinning indicates retinal ganglion cell damage. Teprotumumabs ability to dampen the IGF-IR inflammatory cascade may have reduced retinal inflammation, leading to recovery.
文摘目的:分析甲状腺相关眼病(Graves Ophthalmopathy,GO)患者的全自动非接触眼压计(NCT)与Goldman压平式眼压计(GAT)的测量结果,为临床上甲状腺相关眼病患者的眼压测量方法应用提供理论依据。方法:选择2011年2月-2020年3月期间,就诊于中山大学孙逸仙纪念医院眼科与内分泌科106例(106眼)诊断为甲状腺相关眼病(GO)患者。予以同时应用全自动非接触眼压计(NCT)与Goldman压平式眼压计(GAT)测量双眼眼压,依据GAT结果进行分组,对患者的临床资料进行统计学分析。结果:GO患者的GAT结果较NCT结果偏低(P<0.05)。眼压异常组的GO患者的眼球突出度、临床活动性评分(clinical activity score,CAS)及欧洲Graves眼病专家组(European Group on Graves' Obitopathy,EUGOGO)分级更严重(P均<0.05)。当GO患者的CAS≥3分时,NCT眼压值与GAT眼压值的结果不一致(P<0.05)。结论:当GO患者的CAS≥3分时,应用GAT评估GO患者的眼压。
文摘目的:通过文献荟萃分析评价利妥昔单抗治疗中重度甲状腺相关眼病的疗效。方法:检索中国知网(CNKI)、万方、维普、中国生物医学、PubMed、Web of Science、OVID、Corhone Library、ClinicalTrial.gov等数据库从建库至2019-12-31发表的关于利妥昔单抗治疗中重度甲状腺相关眼病的临床研究。以治疗前后甲状腺相关眼病的临床活动评分为疗效的主要判定指标。将检索到的文献应用RevMan 5.3统计学软件进行分析。结果:纳入了6项研究61例患者,其中2项为随机对照试验,4项为队列研究。Meta分析显示,应用利妥昔单抗治疗中重度甲状腺相关眼病,可使患者的临床活动评分显著降低[SMD=-5.04,95%CI(-7.08^-3.01),P<0.00001]。结论:利妥昔单抗可使中重度甲状腺相关眼病患者的临床活动评分显著下降,对疾病的控制有良好效果。
